Research & Development

German biotechnology business 3B Pharmaceuticals GmbH (3BP) creates targeted radiopharmaceutical medicines and diagnostics for oncology conditions with a high unmet medical need. As a pioneer in peptide optimization and discovery, 3BP has developed a technology platform that covers everything from hit detection to preliminary clinical testing.

Our "disease first" approach to product discovery and development at 4DMT allows us to tailor our AAV vectors to target particular tissue types linked to the underlying condition. This is made possible by our revolutionary discovery platform, Therapeutic Vector Evolution.

With a goal of transforming care for a patient population that is underserved and vulnerable, extending and improving the quality of their lives, restoring their dignity, and lessening the burden on the patient, caregiver, and provider, we are concentrated on bringing innovation to the treatment of cachexia.

Adagene is a Nasdaq-listed, international, clinical-stage immunotherapy firm that is reinventing antibody discovery and design to pave the way for future advancements in the fight against cancer. We develop innovative antibodies that get around safety problems and boost effectiveness to give more cancer patients hope, all thanks to a robust platform integrating computational biology and artificial intelligence.

A biotechnology business called Adcentrx Therapeutics is dedicated to quickening the development of novel protein conjugate therapeutics for cancer and other serious illnesses. Adcentrx aims to create the next generation of tailored medicines by fusing the disease-fighting potency of small molecule payloads with the precise targeting of biologics.

Three FDA-licensed and authorised drugs made by ADMA Biologics, an end-to-end biopharmaceutical firm, include ASCENIVTM (Immune Globulin Intravenous - slra, Human), BIVIGAM® (Immune Globulin Intravenous, Human), and NABI-HB® (hepatitis B immune globulin, human).

The UK-based drug development startup AdoRx Therapeutics is funded by Epidarex Capital and Sixth Element Capital. AdoRx Therapeutics is working to develop novel cancer treatments that target the adenosine pathway. Adenosine is a key component of the tumour microenvironment that helps cancer avoid the immune system.

Adrestia is creating therapies that repair the biological balance in sick, dying, or injured cells in an altogether new way. In order to maintain the health of cells, we are looking for innovative medicines that block or block these damaging processes. It falls within the category of synthetic viability.

In the UK, Akari Therapeutics was founded in 2005. We create complement (C5) and leukotriene (LTB4) pathway-based therapies for autoinflammatory disorders that have the power to change people's lives.

A privately held pharmaceutical company with a cutting-edge approach to medication research is AKL Research & Development Limited. For inflammatory disorders with a high unmet demand, such as osteoarthritis, Alzheimer's, rheumatoid arthritis, and the uncommon connective tissue disease scleroderma, AKLRD is researching innovative treatments.

Berlin-based Alacris Theranostics GmbH was established in 2008 by industry leaders in systems biology, genomics, new generation sequencing applications, and technology development. Since 2000, the company's fundamental technologies have been under constant development.

At Alchemab, we are using the immune system's power to treat disease. By utilising adaptive immunity, nature's most potent search engine, we turn the concept of drug discovery on its head. We find "elite controllers"—or particularly resilient people—and discover how they combat or withstand sickness.